Bioavailability of IgG Administered by the Subcutaneous Route

Abstract

US licensing studies of subcutaneous IgG (SCIG) calculate dose adjustments necessary to achieve area under the curve (AUC) of serum IgG vs. time on SCIG that is non-inferior to that on intravenous IgG (IVIG), within the FDA-set limit of ±20 %. The results are interpreted as showing that different SCIGs differ in bioavailability. We used three approaches to… (More)
DOI: 10.1007/s10875-013-9876-3

Topics

5 Figures and Tables